Japan Based Company, Terumo India, Advances Liver Cancer Care in India with the Launch of Occlusafe and LifePearl
10.11.2023 - 07:05:19
Business Wire India
Terumo India, the Indian arm of Terumo Corporation (TSE: 4543), a global leader in medical technology, recently announced the launch of Occlusafe™ and LifePearl™, intended for use in the management of liver cancer.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with more than 20,000 cases getting added every year in India. HCC can be treated with management approaches ranging from surgical resection to minimally invasive options.
Embolization is one such minimally invasive management option. In this, the blood supply to the tumour is blocked. This deprives the tumour of nutrients and oxygen, which induces the death of these tumour cells. The most common type of Embolization is Transcatheter Arterial Chemo-Embolization (TACE), a clinical-guideline recommended, minimally invasive management option for intermediate stage liver cancer.
For the first time in India, a Japan based company, Terumo, has introduced an advanced therapy called Balloon-TACE (B-TACE) for the management of liver cancer. With Occlusafe™, Terumo’s B-TACE device, patients benefit from more precise and targeted delivery of chemotherapy drug to the tumour. Additionally, damage to surrounding healthy tissues is minimised. This is associated with improved response rates, with significantly fewer repeat treatments required versus TACE alone. This offers the potential to preserve liver function.
helps release chemotherapeutic drug in a controlled and sustained manner at the targeted tumour site inside the liver.
Occlusafe™ and LifePearl™ are known to improve clinical outcomes for liver cancer patients treated with TACE.
Elaborating on the therapy, Shishir Agarwal, MD, Terumo India, said, “At Terumo, our mission is to contribute to society through healthcare. We aim to bring the latest Japanese medical technologies to India to advance the quality of care for patients and physicians. Occlusafe™ and LifePearl™ will offer alternate management options to support liver cancer care in India.”
Terumo India aims to expand its interventional oncology portfolio with novel therapeutic solutions and provide a more comprehensive toolkit for managing cancer care. Its commitment to advancing healthcare in India is built on the foundation of research and cutting-edge technology through a profound understanding of the healthcare system.
Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. With 100 years of experience, Terumo’s extensive medical device portfolio ranges from vascular intervention, cardio-surgical solutions, blood transfusion, and cell therapy technology to medical products essential for daily clinical practice.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with more than 20,000 cases getting added every year in India. HCC can be treated with management approaches ranging from surgical resection to minimally invasive options.
Embolization is one such minimally invasive management option. In this, the blood supply to the tumour is blocked. This deprives the tumour of nutrients and oxygen, which induces the death of these tumour cells. The most common type of Embolization is Transcatheter Arterial Chemo-Embolization (TACE), a clinical-guideline recommended, minimally invasive management option for intermediate stage liver cancer.
For the first time in India, a Japan based company, Terumo, has introduced an advanced therapy called Balloon-TACE (B-TACE) for the management of liver cancer. With Occlusafe™, Terumo’s B-TACE device, patients benefit from more precise and targeted delivery of chemotherapy drug to the tumour. Additionally, damage to surrounding healthy tissues is minimised. This is associated with improved response rates, with significantly fewer repeat treatments required versus TACE alone. This offers the potential to preserve liver function.
helps release chemotherapeutic drug in a controlled and sustained manner at the targeted tumour site inside the liver.
Occlusafe™ and LifePearl™ are known to improve clinical outcomes for liver cancer patients treated with TACE.
Elaborating on the therapy, Shishir Agarwal, MD, Terumo India, said, “At Terumo, our mission is to contribute to society through healthcare. We aim to bring the latest Japanese medical technologies to India to advance the quality of care for patients and physicians. Occlusafe™ and LifePearl™ will offer alternate management options to support liver cancer care in India.”
Terumo India aims to expand its interventional oncology portfolio with novel therapeutic solutions and provide a more comprehensive toolkit for managing cancer care. Its commitment to advancing healthcare in India is built on the foundation of research and cutting-edge technology through a profound understanding of the healthcare system.
Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. With 100 years of experience, Terumo’s extensive medical device portfolio ranges from vascular intervention, cardio-surgical solutions, blood transfusion, and cell therapy technology to medical products essential for daily clinical practice.
About Terumo India (https://terumoindia.com/)
Terumo India is a fast-growing medical devices company that serves to advance access to high-quality Cardiac & Vascular, and other medical devices for patients and medical practitioners in India. Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. Established in 1921 and with its 100 years of history, Terumo’s starting point and unchanging corporate mission has been ‘Contributing to Society through Healthcare’.
Terumo India was established in 2013 with headquarters in Gurgaon, NCR Delhi and has since grown to touch over 100,000 lives with an expanding field force & distribution network. Terumo India is Great Place to Work® certified and has also been recognised as one of India’s Top 15 Workplaces™ in Pharmaceuticals, Healthcare and Biotech 2022. The company runs several acclaimed training & development programs, working closely with its customers and academic partners to contribute to the skilling requirements of India’s healthcare system.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
Terumo India is a fast-growing medical devices company that serves to advance access to high-quality Cardiac & Vascular, and other medical devices for patients and medical practitioners in India. Terumo India is part of Terumo Corporation, a global leader in medical technology with headquarters in Tokyo, Japan. Established in 1921 and with its 100 years of history, Terumo’s starting point and unchanging corporate mission has been ‘Contributing to Society through Healthcare’.
Terumo India was established in 2013 with headquarters in Gurgaon, NCR Delhi and has since grown to touch over 100,000 lives with an expanding field force & distribution network. Terumo India is Great Place to Work® certified and has also been recognised as one of India’s Top 15 Workplaces™ in Pharmaceuticals, Healthcare and Biotech 2022. The company runs several acclaimed training & development programs, working closely with its customers and academic partners to contribute to the skilling requirements of India’s healthcare system.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.
